BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34531456)

  • 1. A forward genetic screen identifies modifiers of rocaglate responsiveness.
    Shen L; Pugsley L; Cencic R; Wang H; Robert F; Naineni SK; Sahni A; Morin G; Zhang W; Nijnik A; Porco JA; Langlais D; Huang S; Pelletier J
    Sci Rep; 2021 Sep; 11(1):18516. PubMed ID: 34531456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.
    Müller C; Obermann W; Schulte FW; Lange-Grünweller K; Oestereich L; Elgner F; Glitscher M; Hildt E; Singh K; Wendel HG; Hartmann RK; Ziebuhr J; Grünweller A
    Antiviral Res; 2020 Mar; 175():104706. PubMed ID: 31931103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
    Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
    Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.
    Chu J; Galicia-Vázquez G; Cencic R; Mills JR; Katigbak A; Porco JA; Pelletier J
    Cell Rep; 2016 Jun; 15(11):2340-7. PubMed ID: 27239032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
    Müller C; Obermann W; Karl N; Wendel HG; Taroncher-Oldenburg G; Pleschka S; Hartmann RK; Grünweller A; Ziebuhr J
    Antiviral Res; 2021 Feb; 186():105012. PubMed ID: 33422611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad anti-pathogen potential of DEAD box RNA helicase eIF4A-targeting rocaglates.
    Obermann W; Azri MFD; Konopka L; Schmidt N; Magari F; Sherman J; Silva LMR; Hermosilla C; Ludewig AH; Houhou H; Haeberlein S; Luo MY; Häcker I; Schetelig MF; Grevelding CG; Schroeder FC; Lau GSK; Taubert A; Rodriguez A; Heine A; Yeo TC; Grünweller A; Taroncher-Oldenburg G
    Sci Rep; 2023 Jun; 13(1):9297. PubMed ID: 37291191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rocaglates Induce Gain-of-Function Alterations to eIF4A and eIF4F.
    Chu J; Zhang W; Cencic R; O'Connor PBF; Robert F; Devine WG; Selznick A; Henkel T; Merrick WC; Brown LE; Baranov PV; Porco JA; Pelletier J
    Cell Rep; 2020 Feb; 30(8):2481-2488.e5. PubMed ID: 32101697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.
    Gupta SV; Sass EJ; Davis ME; Edwards RB; Lozanski G; Heerema NA; Lehman A; Zhang X; Jarjoura D; Byrd JC; Pan L; Chan KK; Kinghorn AD; Phelps MA; Grever MR; Lucas DM
    AAPS J; 2011 Sep; 13(3):357-64. PubMed ID: 21538216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total synthesis of a biotinylated rocaglate: Selective targeting of the translation factors eIF4AI/II.
    Chambers JM; Lindqvist LM; Savage GP; Rizzacasa MA
    Bioorg Med Chem Lett; 2016 Jan; 26(2):262-264. PubMed ID: 26718843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intercepted Retro-Nazarov Reaction: Syntheses of Amidino-Rocaglate Derivatives and Their Biological Evaluation as eIF4A Inhibitors.
    Zhang W; Chu J; Cyr AM; Yueh H; Brown LE; Wang TT; Pelletier J; Porco JA
    J Am Chem Soc; 2019 Aug; 141(32):12891-12900. PubMed ID: 31310112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A.
    Chen M; Asanuma M; Takahashi M; Shichino Y; Mito M; Fujiwara K; Saito H; Floor SN; Ingolia NT; Sodeoka M; Dodo K; Ito T; Iwasaki S
    Cell Chem Biol; 2021 Apr; 28(4):475-486.e8. PubMed ID: 33296667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status.
    Chu J; Cencic R; Wang W; Porco JA; Pelletier J
    Mol Cancer Ther; 2016 Jan; 15(1):136-41. PubMed ID: 26586722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation Inhibition by Rocaglates Activates a Species-Specific Cell Death Program in the Emerging Fungal Pathogen Candida auris.
    Iyer KR; Whitesell L; Porco JA; Henkel T; Brown LE; Robbins N; Cowen LE
    mBio; 2020 Mar; 11(2):. PubMed ID: 32156828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A parasitic fungus employs mutated eIF4A to survive on rocaglate-synthesizing
    Chen M; Kumakura N; Saito H; Muller R; Nishimoto M; Mito M; Gan P; Ingolia NT; Shirasu K; Ito T; Shichino Y; Iwasaki S
    Elife; 2023 Feb; 12():. PubMed ID: 36852480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.
    Iwasaki S; Floor SN; Ingolia NT
    Nature; 2016 Jun; 534(7608):558-61. PubMed ID: 27309803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting eIF4A using rocaglate CR‑1‑31B sensitizes gallbladder cancer cells to TRAIL‑mediated apoptosis through the translational downregulation of c‑FLIP.
    Cao Y; He Y; Yang L; Luan Z
    Oncol Rep; 2021 Jan; 45(1):230-238. PubMed ID: 33416145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity.
    Obermann W; Friedrich A; Madhugiri R; Klemm P; Mengel JP; Hain T; Pleschka S; Wendel HG; Hartmann RK; Schiffmann S; Ziebuhr J; Müller C; Grünweller A
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome.
    Ho JJD; Cunningham TA; Manara P; Coughlin CA; Arumov A; Roberts ER; Osteen A; Kumar P; Bilbao D; Krieger JR; Lee S; Schatz JH
    Cell Rep; 2021 Oct; 37(2):109806. PubMed ID: 34644561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.
    Bordeleau ME; Robert F; Gerard B; Lindqvist L; Chen SM; Wendel HG; Brem B; Greger H; Lowe SW; Porco JA; Pelletier J
    J Clin Invest; 2008 Jul; 118(7):2651-60. PubMed ID: 18551192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategic Diastereoselective C1 Functionalization in the Aza-Rocaglamide Scaffold toward Natural Product-Inspired eIF4A Inhibitors.
    Nilewski C; Michels TD; Xiang AX; Packard GK; Sprengeler PA; Eam B; Fish S; Thompson PA; Wegerski CJ; Ernst JT; Reich SH
    Org Lett; 2020 Aug; 22(16):6257-6261. PubMed ID: 32806219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.